714,226 Shares in Replimune Group, Inc. $REPL Bought by Jefferies Financial Group Inc.

Jefferies Financial Group Inc. bought a new position in Replimune Group, Inc. (NASDAQ:REPL) in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 714,226 shares of the company’s stock, valued at approximately $6,942,000. Jefferies Financial Group Inc. owned about 0.86% of Replimune Group at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Fcpm Iii Services B.V. grew its position in Replimune Group by 6.4% during the 3rd quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock worth $17,424,000 after purchasing an additional 248,672 shares during the period. Vanguard Group Inc. grew its position in Replimune Group by 0.3% during the 3rd quarter. Vanguard Group Inc. now owns 3,479,395 shares of the company’s stock worth $14,579,000 after purchasing an additional 9,707 shares during the period. Braidwell LP grew its position in Replimune Group by 550.3% during the 3rd quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock worth $11,523,000 after purchasing an additional 2,327,205 shares during the period. Balyasny Asset Management L.P. grew its position in Replimune Group by 507.4% during the 3rd quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock worth $11,012,000 after purchasing an additional 2,195,448 shares during the period. Finally, Readystate Asset Management LP grew its position in Replimune Group by 1,296.2% during the 3rd quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock worth $10,982,000 after purchasing an additional 2,433,292 shares during the period. Hedge funds and other institutional investors own 92.53% of the company’s stock.

Replimune Group Price Performance

REPL stock opened at $4.91 on Tuesday. The firm has a market cap of $405.42 million, a PE ratio of -1.43 and a beta of 0.12. The company has a debt-to-equity ratio of 0.33, a quick ratio of 5.60 and a current ratio of 5.60. The firm’s 50 day moving average price is $4.99 and its 200-day moving average price is $7.33. Replimune Group, Inc. has a one year low of $1.50 and a one year high of $13.24.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on REPL. Wall Street Zen raised Replimune Group from a “strong sell” rating to a “sell” rating in a research report on Saturday. HC Wainwright restated a “sell” rating on shares of Replimune Group in a research report on Monday, April 13th. Leerink Partners restated a “market perform” rating and set a $2.00 target price (down from $11.00) on shares of Replimune Group in a research report on Monday, April 13th. Jefferies Financial Group restated a “hold” rating and set a $2.00 target price (down from $13.00) on shares of Replimune Group in a research report on Monday, April 13th. Finally, Wedbush restated a “neutral” rating and set a $2.00 target price (down from $19.00) on shares of Replimune Group in a research report on Monday, April 13th. Six investment analysts have rated the stock with a Hold rating and four have issued a Sell rating to the stock. According to data from MarketBeat.com, Replimune Group has an average rating of “Reduce” and an average target price of $4.75.

Insiders Place Their Bets

In related news, insider Christopher Sarchi sold 6,500 shares of Replimune Group stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $8.01, for a total value of $52,065.00. Following the completion of the sale, the insider owned 151,588 shares in the company, valued at approximately $1,214,219.88. This trade represents a 4.11% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 5.20% of the company’s stock.

Replimune Group Company Profile

Replimune Group, Inc is a clinical?stage biotechnology company focused on developing next?generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.